Clinical Trial Update: Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety and tolerability of gpASIT+TM and gpASIT+TM with an Immunoregulating Adjuvant in seasonal allergic rhinitis (rhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• gpASIT+TM
• gpASIT+TM/Immunoregulating Adjuvant

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Seasonal Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED